openPR Logo
Press release

Peyronie’s Disease Treatment Market Industry Growth?

07-04-2019 12:30 PM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Peyronie’s Disease

Peyronie’s Disease

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie's disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo.

Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/61

On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie's disease. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie's disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

Peyronie’s disease is a rare condition observed in about 6 out of 100 men in the age group of 40 to 70 years. Moreover, the Urology Care Foundation also estimates that the number of people affected by this condition can be higher than this as many men are embarrassed and do not see their healthcare provider. It is mostly at times when the men visit the healthcare practitioner for erectile dysfunction treatment and the healthcare practitioner may notice Peyronie’s disease. Lack of awareness among patients has resulted in under reporting of this condition.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/61

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peyronie’s Disease Treatment Market Industry Growth? here

News-ID: 1796495 • Views: 82

More Releases from Coherent Market Insights (CMI)

Protein Ingredients Market Incredible Possibilities, Growth Analysis And Forecas …
The global protein ingredients market is projected to reach US$ 68.2 billion by the end of 2027, in terms of revenue, growing at CAGR of 6.8% during the forecast period (2019 to 2027). A protein is a macronutrient organic compound that is important for the building of muscles and consist of a chain of amino acids which are organic compounds composed of hydrogen, nitrogen, carbon, and sulfur. Protein can be extracted
Gelatin Market Increasing Demand with Leading Player, Comprehensive Analysis | R …
Gelatin is a soft protein comes from collagen obtained by boiling skin, tendons, ligaments, bones when dissolved with water. It is usually found in animal parts enriched with amino acids (as cows, pigs, and fish). This type of collagen gelatin usually helps to swallow capsules easily. According to varying sources of raw material and processing techniques, gelatin has its additional nutritional value. Gelatin is used for preparation of foods, cosmetics,
Hybrid Seeds Market Growth Rate, Demands, Status And Application Forecast 2027
Hybrid seed are developed artificially by crossing two or more plants of different species. Crossing two different varieties result in development of seed that carries one or more desired traits. Hybrid seeds are majorly used in commercial farming to increase crop yields and to develop disease and climate resistant plants. These seeds are developed by natural methods of cross breeding and they are not genetically modified. Hybrid seeds are majorly
Security Paper Market Potential and Niche Segments, Geographical regions and Tre …
Security paper is a paper which constitutes features that help qualify and identify a document as authentic or original. The use of security paper exemplifies the importance of a document and helps in distinguishing between authentic and counterfeit documents. It is widely used for printing currency, legal, and government documents. Get PDF Brochure(including full TOC, Tables and Figures) @ https://www.coherentmarketinsights.com/insight/request-pdf/561 Counterfeiting of documents and currency has augmented over the recent

All 5 Releases


More Releases for Peyronie

Peyronie’s Disease Treatment Market Set to Encounter Paramount Growth
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market Growing Popularity and Emerging Trend by 2026
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market Is Likely to Witness Tremendous Growth by …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
With Xiaflex the only FDA approved product for this disease, Endo dominates the …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market to Rear Excessive Growth With Key Players …
A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque. "With Xiaflex the only FDA approved product for this disease, Endo dominates the market" The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product.